In men with metastatic castration resistant prostate cancer (mCRPC) and mutations in DNA repair genes like BRCA1, BRCA2, or ATM, the PARP inhibitor olaparib prolongs progression-free survival compared to switching therapy between enzalutamide and abiraterone. TRITON2 was a phase 2 study where 115 men with mCRPC who progressed on 1+ next-generation androgen receptor blockers and a taxane received the PARP inhibitor rucaparib. They had to have a germline or somatic BRCA-mutation to be enrolled. Overall response rate was 43.5%, and 54.8% had a decrease in their PSA of >50%. Median time to PSA progression was 6.5 months. The most significant toxicity was anemia with a grade 3 event in 25%. TRITON3 is comparing rucaparib to next-gen AR blockade in an earlier disease setting. TBL: Rucaparib is another active PARP inhibitor option for men with progressive mCRPC. | Abida, J Clin Oncol 2020


Popular Posts